Positive Results from Two Studies of the PAM50-Based In Vitro Diagnostic Assay will be Presented at the Annual IMPAKT Breast Cancer Conference NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced results from two studies that are featured in oral presentations this week at IMPAKT Breast Cancer Conference...
More...
More...